DPI developer Iconovo announced that it has received its first patent in India covering the company’s ICOone single dose DPI. According to the company, the ICOone platform is already covered by patents in Europe, and patents are pending in the US, China, and Japan. In December 2020, Iconovo announced that Monash University had selected ICOone for delivery of its inhaled dry powder oxytocin for the prevention of postpartum hemorrhage.
Iconovo founder and Chief Technology Officer Orest Lastow commented, “A patent in India is extremely important for us since it is a large potential market for which ICOone is particularly well suited. A cheap, simple and safe way to supply vaccines to a large population is of great interest to many of our potential customers, not the least in India.”
Read the Iconovo press release.
